Markets & Regulations

New contracts boost Lonza

New contracts boost Lonza

Lonza has signed two new agreements for the supply of monoclonal
antibody-based drugs that provide an early fillip for its contract
manufacturing business, which was adversely affected by
overcapacity in 2003.

More heads on the block at DSM

More heads on the block at DSM

DSM will cut around 500 jobs at its Chemelot site in Geleen, the
Netherlands over the next two years, in an effort to cut costs by
over €50 million per annum. The jobs will largely go in support
services and manufacturing staff departments.

Medicare Act costs swelling

Medicare Act costs swelling

The cost of implementing the US Medicare Act - which for the first
time provides a prescription drug benefit for the elderly and
disabled - is rising fast and represents a 'cave-in' to the drug
industry by the US government.

Teva closer to SICOR merger

Teva closer to SICOR merger

Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...